Risk of secondary T-cell malignancy after CAR T-cell therapy | Drug and Therapeutics Bulletin

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Browse

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals More

You are viewing from: Department GEZ-LTA Erasmushogeschool

Citation Tools

DTB select

Risk of secondary T-cell malignancy after CAR T-cell therapy

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Risk of secondary T-cell malignancy after CAR T-cell therapy

Drug and Therapeutics Bulletin Published Online First: 03 June 2025. doi: 10.1136/dtb.2025.000023